SEC Filing Summary: Leap Therapeutics, Inc.
Business Context and Reporting Period
This Form 8-K Current Report was filed by Leap Therapeutics, Inc. on March 27, 2018. The registrant is a Delaware corporation and has elected to be treated as an emerging growth company. The report addresses the closing of a previously announced public offering of common stock.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The document serves as a notification of a corporate event rather than a financial statement.
Material Changes
- Capital Raise: The Company closed its public offering of common stock on March 27, 2018.
- Disclosure: The full details of the offering are contained in the press release filed as Exhibit 99.1, which is incorporated by reference.
Guidance, Outlook, and Risks
The filing does not contain management commentary, financial guidance, or specific risk factors within the body of the report. It refers readers to the attached press release for further details regarding the offering.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) to determine the total number of shares sold and the offering price per share.
- Verify the total gross proceeds raised from the offering.
- Confirm the use of proceeds as outlined in the press release.
- Check subsequent filings for the updated capitalization table and cash position post-offering.